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Abstract: The aim of this study is to investigate the expression of sarcosine metabolism related proteins accord-
ing to androgen receptor (AR) and HER-2 status in estrogen receptor (ER) negative breast cancer and to ana-
lyze its clinical implications. Tissue microarray was constructed for a total of 334 cases of ER negative breast 
cancer. Immunohistochemical stain was conducted for sarcosine metabolism related proteins such as glycine 
N-methyltransferase (GNMT), sarcosine dehydrogenase (SARDH), and l-pipecolic acid oxidase (PIPOX). There were 
131 AR positive, 205 AR negative cases and 143 HER-2 positive, 193 HER-2 negative cases. When subdividing into 
four groups according to AR and HER-2 status, there were 55 AR(+)/HER-2(-) cases, 76 AR(+)/HER-2(+) cases, 67 
AR(-)/HER-2(+) cases and 138 AR(-)/HER-2(-) cases. GNMT and PIPOX expression was highest in the AR(+)/HER-2(-) 
group while expressed lowest in the AR(-)/HER-2(-) group (P<0.001). Stromal PIPOX expression was highest in the 
AR(-)/HER-2(+) group and lowest in the AR(-)/HER-2(-) group (P=0.010). GNMT and PIPOX expression was higher in 
the AR positive group compared with those of AR negative group (P=0.001, and P<0.001, respectively), while tu-
moral and stromal PIPOX expression showed a significant association with HER-2 positivity (P=0.006, and P=0.005, 
respectively). AR positive group had the highest ratio of low sarcosine type while the AR negative group had the high-
est ratio of null type (P<0.001). In conclusion, ER negative breast cancer showed different expression of sarcosine 
metabolism related proteins according to AR and HER-2 status. GNMT and PIPOX expression was high in the AR 
positive group while tumoral and stromal PIPOX expression was high in the HER-2 positive group.
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Introduction
Sarcosine (N-methylglycine) is a non-proteino-
genic amino acid produced through glycine 
metabolism. The major enzymes that play a key 
role in the sarcosine metabolism pathway are 
glycine N-methyltransferase (GNMT), sarcosine 
dehydrogenase (SARDH), and l-pipecolic acid 
oxidase (PIPOX). Within the intracellular envi-
ronment, the methyl group is transferred from 
S-adenosylmethionine to glycine, thereby pro-
ducing sarcosine. The key enzyme that facili-
tates this process is GNMT, while the sarco-
sine-metabolizing enzymes, SARDH and PIPOX, 
produce glycine from sarcosine through oxida-
tive demethylation [1]. Sarcosine is reportedly a 
potential oncometabolite where in prostate 
cancer sarcosine may serve as a possible sen-
sitive tumor biomarker through its role in tumor 
progression and metastasis [2, 3] (Figure 1). 
It is well known that steroidal hormones, such 
as estrogen, play an important role in the patho-
genesis of breast cancer, therefore evaluation 
of estrogen receptor (ER) and progesterone 
receptor (PR) is essential to the treatment and 
prognosis of breast cancer. Apart from the well-
known ER and PR receptors, the androgen 
receptor (AR) is also one of the steroid hormon-
al subfamily with its role in carcinogenesis, yet 
unknown. AR expression in breast cancer is 
purported to be about 70% [4], while in apo-
crine type, lobular type breast cancers, its 
expression is known to be even higher [5]. In 
the investigation of AR and breast cancer char-
acteristics, Farmer et al. subdivided a new sub-
group of breast cancer through gene clustering 
analysis-the molecular apocrine breast cancer 
(MABC). MABC takes up about 8-14% of breast 
cancers characterized by apocrine histological 
features, androgen receptor (AR) positivity, 
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estrogen receptor (ER) negativity [6]. MABC is 
frequently associated with HER-2 overexpres-
sion/amplification and is related to poor long-
term survival [6]. To note, although MABC was 
originally described via gene clustering analy-
sis, it may also be identified through surrogate 
immunohistochemical markers, in which it is 
ER negative and AR positive [6, 7]. While taking 
note of previous studies that investigated the 
role of AR, HER-2 and sarcosine regarding pros-
tate cancer [8], there may be a similar link 
amongst AR, HER-2 and sarcosine in breast 
cancers. This study therefore aims to investi-
gate the expressions of sarcosine metabolism 
related proteins according to AR and HER-2 sta-
tus in ER negative breast cancers and under-
stand its clinical implications.
Material and methods
Patient selection and clinicopathologic evalu-
ation
Formalin-fixed paraffin-embedded tissue sam-
ples of patients diagnosed with invasive ductal 
ining were selected. A cut-off value of 1% or 
more positively stained nuclei was used to 
define ER and AR positivity [9]. HER-2 staining 
was analyzed according to the American Society 
of Clinical Oncology (ASCO)/College of American 
Pathologists (CAP) guidelines using the follow-
ing categories: 0 = no immunostaining; 1+ = 
weak incomplete membranous staining, in less 
than 10% of tumor cells; 2+ = complete mem-
branous staining, either uniform or weak in at 
least 10% of tumor cells; and 3+ = uniform 
intense membranous staining in at least 10% 
of tumor cells [10]. HER-2 immunostaining was 
considered positive when strong (3+) membra-
nous staining was observed whereas cases 
with 0 to 1+ were regarded as negative. The 
cases showing 2+ HER-2 expression were eval-
uated for HER-2 amplification by Fluorescent in 
situ hybridization (FISH). All cases were retro-
spectively reviewed by a breast pathologist 
(Koo JS), in which histological evaluation was 
based on hematoxlin and eosin (H&E) stained 
slides. The histological grade was assessed 
using the Nottingham grading system [11]. 
Figure 1. Schematic representation of sarcosine pathway. 
Table 1. Source, clone, and dilution of antibodies used in this study
antibody company clone dilution
AR Lab Vision Corp. AR441 1:100
HER-2 DAKO, Glostrup, Denmark Polyclonal 1:1500
Ki-67 DAKO, Glostrup, Denmark MIB-1 1:150
Sarcosine metabolism related
    GNMT Abcam, Cambridge, UK Polyclonal 1:100
    SARDH Abcam, Cambridge, UK Polyclonal 1:100
    PIPOX Abcam, Cambridge, UK Polyclonal 1:100
Glycine N-methyltransferase (GNMT), sarcosine dehydrogenase (SARDH), and l-pipecolic 
acid oxidase (PIPOX), androgen receptor (AR).
carcinoma, no specific 
type, from January 2010 
to December 2012 at 
Severance Hospital were 
included in this study. The 
study was approved by the 
Institutional Review Board 
of Severance Hospital. 
Those cases that had un- 
dergone pre-operative ch- 
emotherapy were exclud-
ed and only those that 
showed ER negativity in 
immunohistochemical sta- 
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Table 2. Clinicopathologic characteristics according to the AR and HER-2 status in ER negative breast 
cancer 
Parameters Total  N=336 (%)
AR positive group n=131 AR negative group n=205
p- 
value*
p- 
value†HER-2-  
n=55 (%)
HER-2+  
n=76 (%) p-value
HER-2+  
n=67 (%)
HER-2-  
n=138 (%) p-value
Age (years) 0.927 0.019 0.001 0.002
    ≤35 34 (10.1) 2 (3.6) 3 (3.9) 4 (6.0) 25 (18.1)
    >35 302 (89.9) 53 (96.4) 73 (96.1) 63 (94.0) 113 (81.9)
Histologic grade 0.890 0.073 0.121 0.102
    I/II 138 (41.1) 26 (47.3) 35 (46.1) 31 (46.3) 46 (33.3)
    III 198 (58.9) 29 (52.7) 41 (53.9) 36 (53.7) 92 (66.7)
T stage 0.731 0.094 0.202 0.191
    T1 162 (48.2) 28 (50.9) 41 (53.9) 36 (53.7) 57 (41.3)
    T2/T3 174 (51.8) 27 (49.1) 35 (46.1) 31 (46.3) 81 (58.7)
Lymph node metastasis 0.953 0.328 0.712 0.533
    No 245 (72.9) 41 (74.5) 57 (75.0) 51 (76.1) 96 (69.6)
    Yes 91 (27.1) 14 (25.5) 19 (25.0) 16 (23.9) 42 (30.4)
Tumor recurrence 0.615 0.824 0.900 0.582
    No 296 (88.1) 50 (90.9) 67 (88.2) 59 (88.1) 120 (87.0)
    Yes 40 (11.9) 5 (9.1) 9 (11.8) 8 (11.9) 18 (13.0)
Patient death 0.791 0.393 0.280 0.088
    No 304 (90.5) 52 (94.5) 71 (93.4) 61 (91.0) 120 (87.0)
    Yes 32 (9.5) 3 (5.5) 5 (6.6) 6 (9.0) 18 (13.0)
Ki-67 LI (%) 0.228 0.001 <0.001 <0.001
    ≤14 80 (23.8) 23 (41.8) 24 (31.6) 19 (28.4) 14 (10.1)
    >14 256 (76.2) 32 (58.2) 52 (68.4) 48 (71.6) 124 (89.9)
Chemotherapy 0.865 0.618 0.170 0.029
    No 58 (17.3) 13 (23.6) 17 (22.4) 8 (11.9) 20 (14.5)
    Yes 278 (82.7) 42 (76.4) 59 (77.6) 59 (88.1) 118 (85.5)
Radiotherapy 0.046 0.018 0.022 0.968
    No 156 (46.4) 20 (36.4) 41 (53.9) 39 (58.2) 56 (40.6)
    Yes 180 (53.6) 35 (63.6) 35 (46.1) 28 (41.8) 82 (59.4)
Significant (< 0.05) P values are shown in bold. *P value was determined by comparing the four groups defined by AR and HER-2 status. †P value was determined by 
comparing AR+ and AR- groups by Fisher’s exact test.
Tumor staging was based on the 7th American 
Joint Committee on Cancer (AJCC) criteria. 
Disease-free survival (DFS) was calculated 
from the date of the first curative surgery to the 
date of the first loco-regional or systemic 
relapse, or death without any type of relapse. 
Overall survival (OS) was estimated from the 
date of the first curative operation to the date 
of the last follow-up or death from any cause. 
Clinicopathologic parameters evaluated in 
each breast cancer included patient age at ini-
tial diagnosis, lymph node metastasis, tumor 
recurrence, distant metastasis, and survival.
Tissue microarray
After reviewing H&E-stained slides, the most 
suitable formalin-fixed paraffin-embedded (FF- 
PE) tumor tissue samples were selected. The 
most representative tumor region on the FFPE 
sample was then marked and a 3-mm tissue 
core sample was extracted using a punch 
machine and planted onto a 6 × 5 recipient 
block. A total of 2 tissue cores were taken for all 
samples in this TMA construction. 
Immunohistochemistry 
The antibodies used for immunohistochemistry 
in this study are shown in Table 1. Formalin-
fixed, paraffin-embedded tissue sections were 
used for immunohistochemical staining. FFPE 
blocks were sectioned at a thickness of 3 um 
and then deparaffinized and rehydrated using 
xylene and alcohol solutions. Sections were 
then stained using the Ventana Discoversy XT 
automated stainer (Ventana Medical System, 
Tucson, AZ, USA). Antigen retrieval was achi- 
eved by soaking sections in a CC1 buffered 
solution (Cell Conditioning 1; citrate buffer Ph 
6.0, Ventan Medical System). The appropriate 
positive and negative controls were included 
together with the study sample for staining. 
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Table 3. Expression of sarcosine metabolism-related proteins according to the AR and HER-2 status in 
ER negative breast cancer
Parameters Total  N=336 (%)
AR positive group n=131 AR negative group n=205
p-value* p-value†HER-2-  
n=55 (%)
HER-2+  
n=76 (%) p-value
HER-2+  
n=67 (%)
HER-2-  
n=138 (%) p-value
GNMT 0.051 0.006 <0.001 0.001
    Negative 308 (91.7) 43 (78.2) 69 (90.8) 60 (89.6) 136 (98.6)
    Positive 28 (8.3) 12 (21.8) 7 (9.2) 7 (10.4) 2 (1.4)
SARDH 0.811 1.000 0.689 0.256
    Negative 291 (86.6) 47 (85.5) 63 (82.9) 59 (88.1) 122 (88.4)
    Positive 45 (13.4) 8 (14.5) 13 (17.1) 8 (11.9) 16 (11.6)
PIPOX (T) 0.104 0.002 <0.001 <0.001
    Negative 214 (63.7) 17 (30.9) 35 (46.1) 44 (65.7) 118 (85.5)
    Positive 122 (36.3) 38 (69.1) 41 (53.9) 23 (34.3) 20 (14.5)
PIPOX (S) 0.802 0.003 0.010 0.102
    Negative 299 (89.0) 48 (87.3) 64 (84.2) 55 (82.1) 132 (95.7)
    Positive 37 (11.0) 7 (12.7) 12 (15.8) 12 (17.9) 6 (4.3)
Significant (< 0.05) P values are shown in bold. *P value was determined by comparing the four groups defined by AR and 
HER-2 status. †P value was determined by comparing AR+ and AR- groups by Fisher’s exact test. glycine N-methyltransferase 
(GNMT), sarcosine dehydrogenase (SARDH), and l-pipecolic acid oxidase (PIPOX), androgen receptor (AR).
Figure 2. Immunohistochemical results for sarcosine metabolism-related proteins according to AR and HER-2 status 
in ER negative breast cancer. GNMT and PIPOX expression is highest in the AR(+)/HER-2(-) group, while it is lowest 
in the AR(-)/HER-2(-) group (P<0.001). Also in stromal PIPOX expression is highest in the AR(-)/HER-2(+) group and 
lowest in the AR(-)/HER-2(-) group.
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Interpretation of immunohistochemical results
Immunohistochemical markers for GNMT, 
SARDH and PIPOX were accessed by light 
microscopy. The result was recorded as the 
multiplied score of the proportion of stained 
cell to immunostaining intensity. The propor-
tion of stained cells was scored according to a 
three tiered system ranging from 0 to 2, defined 
as follows; 0 represented negative results, 1 
represented less than 30% of cells stained, 
and 2 represented more than 30% of cells 
stained. Immunostaining intensity was sc- 
ored according to a four tiered system ranging 
from 0 to 3 defined as follows: 0 represented 
negative result, 1 represented weak, 2 repre-
sented moderate, and 3 represented strong 
intensities. The number obtained after the mul-
Table 4. Sarcosine metabolism phenotypes according to the AR and HER-2 status in ER negative 
breast cancer
Parameters Total  N=336 (%)
AR positive group n=131 AR negative group n=205
p-value* p-value†HER-2-  
n=55 (%)
HER-2+  
n=76 (%) p-value
HER-2+  
n=67 (%)
HER-2-  
n=138 (%) p-value
Sarcosine metabolic type 0.066 0.002 <0.001 <0.001
    High sarcosine type 10 (3.0) 1 (1.8) 2 (2.6) 6 (9.0) 1 (0.7)
    Low sarcosine type 129 (38.4) 31 (56.4) 41 (53.9) 24 (35.8) 33 (23.9)
    Intermediate sarcosine type 18 (5.4) 11 (20.0) 5 (6.6) 1 (1.5) 1 (0.7)
    Null type 179 (53.3) 12 (21.8) 28 (36.8) 36 (53.7) 103 (74.6)
Significant (< 0.05) P values are shown in bold. *P value was determined by comparing the four groups defined by AR and HER-2 status. †P value was determined by com-
paring AR+ and AR− groups by Fisher’s exact test.
Figure 3. Correlation between clinicopathologic parameters and expression of sarcosine metabolism-related pro-
teins in ER negative breast cancer.
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tiplication of stained 
cell proportion by im- 
munostaining intensity 
resulted in the overall 
interpretation score: 
0-1 was defined as neg-
ative, 2-6 positive [12]. 
Ki-67 labeling indices 
(LI) were scored by 
counting the number of 
positively stained nu- 
clei and expressed as a 
percentage of total 
tumor cells. 
Sarcosine metabolism 
phenotype
Through immunohisto-
chemical staining of 
GNMT, SARDH and 
PIPOX markers, sarco-
sine metabolism phe-
notypes were classified 
as follows; high sarco-
sine type: GNMT(+)/
SARDH and PIPOX(-), 
Figure 4. Correlation between clinicopathologic parameters and expression of sarcosine metabolism-related pro-
teins in AR negative (A), AR positive (B, C), and AR(+)/HER-2(+) group (D, E).
Table 5. Univariate analysis by log-rank test of the impact of sarcosine 
metabolism-related protein expression in estrogen receptor negative 
breast cancer on prognosis
Parameters
Disease-free survival Overall-survival
95% CI p-value 95% CI p-value
GNMT 0.417 0.491
    Negative 117 (111-124) 124 (118-130)
    Positive 90 (74-105) 114 (95-133)
SARDH 0.348 0.951
    Negative 116 (109-123) 124 (119-130)
    Positive 117 (105-130) 115 (102-128)
PIPOX (T) 0.837 0.519
    Negative 119 (113-125) 123 (117-129)
    Positive 108 (100-116) 118 (108-128)
PIPOX (S) 0.995 0.571
    Negative 117 (109-124) 123 (117-129)
    Positive 115 (100-129) 122 (108-135)
Sarcosine metabolic type 0.452 0.822
    High sarcosine type 70 (50-89) 77 (60-93)
    Low sarcosine type 110 (100-120) 113 (103-124)
    Intermediate sarcosine type 100 (88-112) 122 (105-140)
    Null type 120 (113-127) 125 (118-131)
Glycine N-methyltransferase (GNMT), sarcosine dehydrogenase (SARDH), and l-pipecolic 
acid oxidase (PIPOX), androgen receptor (AR).
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low sarcosine type: GNMT(-)/SARDH or PIPOX(+), 
intermediate sarcosine type: GNMT(+)/SARDH 
or PIPOX(+), and null type: GNMT(-)/SARDH and 
PIPOX(-).
Statistical analysis   
Data was analyzed using SPSS for Windows 
version 12.0 (SPSS Inc., Chicago, IL). Student’s 
t test and Fisher’s exact test were used for con-
tinuous and categorical variables, respectively. 
To analyze data with multiple comparisons, a 
corrected p-value with application of the 
Bonferroni method for multiple comparisons 
was used. Statistical significance was assumed 
when P<0.05. Kaplan-Meier survival curves 
and log-rank statistics were employed to evalu-
ate time to tumor metastasis and time to sur-
vival. Multivariate regression analysis was per-
formed using Cox proportional hazards model.
Results 
Basal characteristics of patients according to 
the AR and HER-2 status in ER negative breast 
cancer
Within the current study, there were 131 AR 
positive cases, 205 AR negative cases, 143 
HER-2 positive cases and 193 HER-2 negative 
cases (Table 2). After subdividing into four 
groups according to AR and HER-2 status, there 
were 55 cases in AR(+)/HER-2(-) group, 76 
cases in AR(+)/HER-2(+) group, 67 cases in 
AR(-)/HER-2(+) group, and 138 cases in AR(-)/
HER-2(-) group. Clinicopathologic analysis 
amongst the four groups revealed that AR(-)/
HER-2(-) group was associated with younger 
age and higher Ki-67 LI, (P=0.001, and 
P<0.001, respectively). Direct comparisons 
between AR positive group and AR negative 
group showed that AR negative group was 
associated with old age and higher Ki-67 LI 
(P=0.002, and P<0.001, respectively). Within 
AR negative group, HER-2 positive group tend-
ed to have older aged patients (P=0.019) while 
in the HER-2 negative group, Ki-67 LI was sig-
nificantly higher (P=0.001).
The expression of sarcosine metabolism-re-
lated proteins according to the AR and HER-2 
status in ER negative breast cancer
Sarcosine metabolism related protein expres-
sions in ER negative breast cancers, according 
to AR and HER-2 status were as follows (Table 
3 and Figure 2): GNMT and PIPOX expression 
was highest in the AR(+)/HER-2(-) group, while it 
was lowest in the AR(-)/HER-2(-) group 
(P<0.001). Also stromal PIPOX expression was 
highest in the AR(-)/HER-2(+) group and lowest 
in the AR(-)/HER-2(-) group (P=0.010). GNMT 
Table 6. Univariate analysis by log-rank test of the impact of sarcosine metabolism-related protein 
expression in estrogen receptor negative breast cancer on prognosis according to AR status
Parameters
AR positive AR negative
Disease-free survival Overall-survival Disease-free survival Overall-survival
95% CI p-value 95% CI p-value 95% CI p-value 95% CI p-value
GNMT 0.946 0.757 0.180 0.122
    Negative 91 (83-98) 120 (105-134) 118 (111-126) 122 (116-128)
    Positive 93 (76-110) 120 (99-141) 71 (48-93) 71 (50-92)
SARDH 0.521 0.366 0.411 0.574
    Negative 90 (82-98) 119 (104-134) 117 (108-125) 123 (117-128)
    Positive 97 (84-109) 121 (101-140) 118 (103-134) 111 (94-128)
PIPOX (T) 0.502 0.152 0.436 0.483
    Negative 88 (78-98) 116 (100-132) 120 (113-127) 122 (116-129)
    Positive 96 (87-104) 128 (122-135) 106 (93-120) 108 (94-121)
PIPOX (S) 0.877 0.999 0.879 0.508
    Negative 91 (84-98) 121 (107-135) 117 (109-125) 121 (115-127)
    Positive 92 (73-111) 118 (94-142) 116 (98-135) 123 (109-137)
Sarcosine metabolic type 0.806 N/A N/A <0.001
    High sarcosine type 77 (55-98) N/A N/A 79 (60-97)
    Low sarcosine type 88 (79-96) N/A N/A 112 (100-124)
    Intermediate sarcosine type 100 (87-112) N/A N/A 22 (22-22)
    Null type 87 (75-100) N/A N/A 124 (118-130)
Glycine N-methyltransferase (GNMT), sarcosine dehydrogenase (SARDH), and l-pipecolic acid oxidase (PIPOX), androgen receptor (AR).
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and PIPOX expressions were higher in AR posi-
tive group than in AR negative group (P=0.001, 
and P<0.001, respectively), while within the AR 
negative group, GNMT was highly expressed 
when HER-2 was positive (P=0.006). Within the 
AR negative group, turmoral and stromal PIPOX 
expressions were both higher in the HER-2 pos-
itive than in the HER-2 negative group (P=0.002, 
and P=0.003, respectively).
Sarcosine metabolism phenotypes according 
to the AR and HER-2 status in ER negative 
breast cancer
ER negative breast cancer was evaluated 
according to the sarcosine metabolism pheno-
type as defined through immunohistochemical 
staining results of GNMT, SARDH and PIPOX 
(Table 4). The results were analyzed according 
to AR and HER-2 status, in which AR positive 
group had the highest rate of low sarcosine 
type, while in the AR negative group had the 
highest rate of null type (P<0.001). Within the 
given data set, there were a total of 278 cases 
that had received chemotherapy (82.7%) and 
180 cases that had received radiotherapy 
(53.6%). Statistical analysis revealed that AR 
positive group had received chemotherapy sig-
nificantly more than the AR negative group 
(P=0.029) and that radiotherapy was conduct-
ed more in the HER-2 negative groups than 
HER-2 positive groups (P=0.046, and P=0.018, 
respectively). 
Correlation between clinicopathologic param-
eters and expression of sarcosine metabolism-
related proteins in ER negative breast cancer
In the investigation between sarcosine metabo-
lism-related proteins and clinicopathologic fac-
tors in ER negative breast cancer, GNMT 
expression was associated with higher Ki-67 LI 
(P=0.036), SARDH expression with lymph node 
metastasis (P=0.028), and tumoral and stro-
mal PIPOX expression with HER-2 positivity 
(P=0.006, and P=0.005, respectively, Figure 
3). 
In the analysis according to AR status, the AR 
negative group showed that GNMT expression 
was associated with lower Ki-67 LI (P=0.024), 
while within the AR positive group, SARDH posi-
tivity and tumoral PIPOX negativity was associ-
ated with lymph node metastasis (P=0.004, 
and P=0.008, respectively). AR(+)/HER-2(+) 
group showed that tumoral PIPOX positivity was 
associated with higher histological grade 
(P=0.044), while SARDH expression was asso-
ciated with lymph node metastasis (P=0.008, 
Figure 4). 
Table 7. Univariate analysis by log-rank test of the impact of sarcosine metabolism-related protein 
expression in estrogen receptor negative breast cancer on prognosis according to HER-2 status
Parameters
HER-2 positive HER-2 negative
Disease-free survival Overall-survival Disease-free survival Overall-survival
95% CI p-value 95% CI p-value 95% CI p-value 95% CI p-value
GNMT 0.232 0.371 0.854 0.977
    Negative 112 (102-121) 124 (114-133) 118 (110-126) 121 (115-128)
    Positive 81 (57-105) 106 (75-137) 84 (72-96) 84 (72-96)
SARDH 0.160 0.334 0.986 0.493
    Negative 83 (75-90) 120 (109-131) 119 (110-127) 123 (117-129)
    Positive 124 (112-136) 124 (110-138) 87 (78-96) 106 (90-123)
PIPOX (T) 0.906 0.343 0.802 0.892
    Negative 110 (99-121) 120 (108-132) 121 (113-128) 121 (114-128)
    Positive 91 (79-103) 121 (107-135) 111 (101-120) 114 (105-123)
PIPOX (S) 0.993 0.909 0.851 N/A
    Negative 85 (78-92) 122 (112-133) 118 (110-126) N/A
    Positive 112 (93-131) 117 (98-135) 89 (75-103) N/A
Sarcosine metabolic type N/A N/A N/A N/A
    High sarcosine type N/A N/A N/A N/A
    Low sarcosine type N/A N/A N/A N/A
    Intermediate sarcosine type N/A N/A N/A N/A
    Null type N/A N/A N/A N/A
Glycine N-methyltransferase (GNMT), sarcosine dehydrogenase (SARDH), and l-pipecolic acid oxidase (PIPOX), androgen receptor (AR).
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The impact of expression of sarcosine metab-
olism-related proteins on disease-free survival 
in ER negative breast cancer
In univariate analysis of the prognostic power 
of sarcosine metabolism-related proteins in ER 
negative breast cancer showed no statistically 
significant findings (Table 5).
In univariate analysis of the prognostic power 
of sarcosine metabolism-related proteins 
according to the status of AR and HER-2, AR 
negative group showed a difference in OS 
according to sarcosine metabolic type. The sar-
cosine metabolic types in order of shorter OS 
are as follows; intermediate sarcosine type, 
high sarcosine type, low sarcosine type and null 
type (P<0.001, and Table 6). There was no 
prognostic difference in sarcosine metabolism-
related proteins according to HER-2 status 
(Table 7). 
Discussion
In the current study regarding ER negative 
breast cancers, sarcosine metabolism related 
protein expression was analyzed according to 
AR and HER-2 status. AR and sarcosine metab-
olism related protein expression was found to 
have significant relationships with each other. 
GNMT and PIPOX expression was higher in the 
AR positive group compared to AR negative 
group. Although there are no studies dealing 
with sarcosine metabolism-related proteins in 
breast cancers for direct comparison, sarco-
sine metabolism studies on prostate cancers 
may serve as a good hypothetical clue. In pros-
tate cancers, increased sarcosine level was 
associated with cancer progression. When sar-
cosine was injected into a benign prostate cell, 
the cell had transformed to an invasive pheno-
type [1], and also reported an increased sarco-
sine level within prostate cancer tissues [13]. 
Also, in both in vitro and in vivo models sarco-
sine was shown to be associated with prostate 
cancer growth and progression [2]. In the cur-
rent study, sarcosine level was not evaluated 
directly from breast cancer tissues, but instead, 
sarcosine metabolism-related proteins, such 
as GNMT, SARDH and PIPOX were measured 
semi-quantitatively through immunohistochem-
ical staining. However, in the study based on 
prostate cancer showed that such sarcosine 
metabolism-related proteins did correlate well 
with sarcosine activity level; the sarcosine gen-
erating enzyme, GNMT, expression was high in 
the cancer tissue compared to normal prostate 
tissue, while sarcosine metabolizing enzymes, 
such as SARDH and PIPOX, expression was low 
[2]. In the current study, expressions of AR and 
sarcosine metabolism related proteins were 
found to be intricately related. In the previously 
reported study regarding prostate cancer cells, 
androgen had increased expression of GNMT 
through AR, which was attributed to the fact 
that androgen response element exists on the 
first exon coding region of GNMT [14]. Therefore 
AR was assumed to play a key role in the 
expression of sarcosine metabolism related 
proteins in prostate cancers, a finding that par-
allels with our results. However in the current 
study, not only did GNMT, a sarcosine increas-
ing substance, but PIPOX, a sarcosine metabo-
lizing enzyme had increased in AR positive 
cases, that calls for further investigations into 
the relationship between AR and sarcosine lev-
els in breast cancer. Sarcosine phenotypes, 
classified according to expressions of sarco-
sine metabolism related proteins, revealed dis-
tinctive associations with AR status. AR posi-
tive group had a high proportion of low sarco-
sine types, while the AR negative group, null 
type had the highest proportion. Because the 
null type is the group where GNMT, SARDH and 
PIPOX are all negative, in the case when AR is 
positive, sarcosine metabolism related activity 
would be expected to be increased compared 
to AR negative groups. 
In the current study, the relationship between 
HER-2 and sarcosine metabolism related pro-
tein expression was significantly different 
according to AR status. Within AR negative 
group, GNMT and PIPOX were both highly 
expressed in the HER-2 positive group than in 
HER-2 negative group. Although in breast can-
cers, the exact mechanism and association 
between HER-2 and sarcosine metabolism 
related protein expression is not yet known, 
previous studies on prostate cancer reported 
that sarcosine increased both HER-2 mRNA 
and protein expressions [8]. In this study, AR 
status explains the relationship between HER-2 
and sarcosine metabolism related protein 
expressions. In previous reports that describe 
molecular apocrine breast cancer (MABC) as a 
unique entity of ER negative breast cancers 
with AR positivity [i.e. ER(-)/AR(+)] and apocrine 
histological features, about 20-50% is reported 
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to have HER-2 overexpression/amplification [6, 
7]. Therefore, ER(-)/AR(+) group and ER(-)/AR(-) 
group would be expected to have different fea-
tures. In this study, the ER(-)/AR(-) group showed 
a difference in expression between GNMT and 
PIPOX according to HER-2 status, while in the 
ER(-)/AR(+) group (MABC), there was no signifi-
cant difference according to HER-2 status. 
Although HER-2 status is an important bio-
marker that characterizes breast cancers, in 
MABC, there was no significant difference 
between HER-2 positive and negative groups 
[6], consistent with the findings of this study. 
In conclusion, in ER negative breast cancers, 
expression of sarcosine metabolism related 
proteins is different according to AR status; in 
the AR positive group, GNMT and PIPOX expres-
sion was higher than in those of the AR nega-
tive group. Within the AR negative group, GNMT 
and PIPOX were both highly expressed in the 
HER-2 positive group than in HER-2 negative 
group.
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